These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37079211)

  • 1. DC vaccine enhances CAR-T cell antitumor activity by overcoming T cell exhaustion and promoting T cell infiltration in solid tumors.
    Zhang M; Wang Y; Chen X; Zhang F; Chen J; Zhu H; Li J; Chen Z; Wang A; Xiao Y; Chen Z; Dong Y; Yin X; Ji F; Liu J; Liang J; Pan F; Guo Z; He L
    Clin Transl Oncol; 2023 Oct; 25(10):2972-2982. PubMed ID: 37079211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor.
    Sun S; Ding Z; Gao L; Hammock BD; Huang X; Xu ZP; Wang X; Cheng Q; Mo F; Shi W; Xie S; Liu A; Li H; Yang X; Lu X
    Theranostics; 2023; 13(14):5099-5113. PubMed ID: 37771772
    [No Abstract]   [Full Text] [Related]  

  • 3. Coexpression of
    Xu T; Wang C; Chen X; Bai J; Wang E; Sun M
    Immunotherapy; 2022 Dec; 14(18):1457-1466. PubMed ID: 36597720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors.
    Yang F; Zhang F; Ji F; Chen J; Li J; Chen Z; Hu Z; Guo Z
    Front Immunol; 2023; 14():1175920. PubMed ID: 37359558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity.
    Ma L; Hostetler A; Morgan DM; Maiorino L; Sulkaj I; Whittaker CA; Neeser A; Pires IS; Yousefpour P; Gregory J; Qureshi K; Dye J; Abraham W; Suh H; Li N; Love JC; Irvine DJ
    Cell; 2023 Jul; 186(15):3148-3165.e20. PubMed ID: 37413990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesothelin-targeted CAR-T cell therapy for solid tumors.
    Klampatsa A; Dimou V; Albelda SM
    Expert Opin Biol Ther; 2021 Apr; 21(4):473-486. PubMed ID: 33176519
    [No Abstract]   [Full Text] [Related]  

  • 7. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
    Gumber D; Wang LD
    EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
    Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
    Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells.
    Tokatlian T; Asuelime GE; Mock JY; DiAndreth B; Sharma S; Toledo Warshaviak D; Daris ME; Bolanos K; Luna BL; Naradikian MS; Deshmukh K; Hamburger AE; Kamb A
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer.
    Zhao R; Cui Y; Zheng Y; Li S; Lv J; Wu Q; Long Y; Wang S; Yao Y; Wei W; Yang J; Wang BC; Zhang Z; Zeng H; Li Y; Li P
    Front Immunol; 2021; 12():660488. PubMed ID: 34326835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia.
    Wu M; Zhang L; Zhang H; Ning J; Tu S; He Y; Li Y
    Cytotherapy; 2019 Jun; 21(6):659-670. PubMed ID: 31031152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene modification strategies for next-generation CAR T cells against solid cancers.
    Tian Y; Li Y; Shao Y; Zhang Y
    J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models.
    Schoutrop E; Poiret T; El-Serafi I; Zhao Y; He R; Moter A; Henriksson J; Hassan M; Magalhaes I; Mattsson J
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exhaustion, rather than lack of infiltration and persistence, of CAR-T cells hampers the efficacy of CAR-T therapy in an orthotopic PDAC xenograft model.
    Takeuchi Y; Wang Y; Sasaki K; Sato O; Tsuchikawa T; Wang L; Amaishi Y; Okamoto S; Mineno J; Hirokawa Y; Hatanaka KC; Hatanaka Y; Kato T; Shiku H; Hirano S
    Biomed Pharmacother; 2024 Jan; 170():116052. PubMed ID: 38141280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
    Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
    Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors.
    Cherkassky L; Hou Z; Amador-Molina A; Adusumilli PS
    Cancer Cell; 2022 Jun; 40(6):569-574. PubMed ID: 35487216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor.
    Gao G; Liao W; Shu P; Ma Q; He X; Zhang B; Qin D; Wang Y
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37591632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Making CAR T Cells a Solid Option for Solid Tumors.
    Schmidts A; Maus MV
    Front Immunol; 2018; 9():2593. PubMed ID: 30467505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy.
    Zhang E; Yang P; Gu J; Wu H; Chi X; Liu C; Wang Y; Xue J; Qi W; Sun Q; Zhang S; Hu J; Xu H
    J Hematol Oncol; 2018 Aug; 11(1):102. PubMed ID: 30103775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.